PE20171319A1 - Composiciones dispersables - Google Patents
Composiciones dispersablesInfo
- Publication number
- PE20171319A1 PE20171319A1 PE2017001255A PE2017001255A PE20171319A1 PE 20171319 A1 PE20171319 A1 PE 20171319A1 PE 2017001255 A PE2017001255 A PE 2017001255A PE 2017001255 A PE2017001255 A PE 2017001255A PE 20171319 A1 PE20171319 A1 PE 20171319A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- refers
- layer
- dispersible compositions
- dispersible
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 229960001137 bedaquiline fumarate Drugs 0.000 abstract 1
- ZLVSPMRFRHMMOY-WWCCMVHESA-N bedaquiline fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1([C@H](C2=CC3=CC(Br)=CC=C3N=C2OC)[C@@](O)(CCN(C)C)C=2C3=CC=CC=C3C=CC=2)=CC=CC=C1 ZLVSPMRFRHMMOY-WWCCMVHESA-N 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- -1 glidants Substances 0.000 abstract 1
- 239000003906 humectant Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Lubricants (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referido a una composicion dispersable que comprende: fumarato de bedaquilina; una capa intragranular; y una capa extragranular, donde ambas capas comprenden un excipiente/diluyente no soluble tal como celulosa microcristalina. Ademas, dicha composicion comprende disgregantes, deslizantes, humectantes o tensioactivos, aglutinantes o polimeros, lubricantes y disolventes. Tambien se refiere a un procedimiento de preparacion. Dicha composicion es util en el tratamiento de la tuberculosis, sobretodo en poblaciones pediatricas y geriatricas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN264MU2015 | 2015-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20171319A1 true PE20171319A1 (es) | 2017-09-07 |
Family
ID=55229712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2017001255A PE20171319A1 (es) | 2015-01-27 | 2016-01-26 | Composiciones dispersables |
Country Status (29)
Country | Link |
---|---|
US (2) | US20180000810A1 (es) |
EP (1) | EP3250182B1 (es) |
JP (3) | JP7291458B2 (es) |
KR (1) | KR102631986B1 (es) |
CN (2) | CN107205945A (es) |
AU (2) | AU2016212116B2 (es) |
CA (1) | CA2973301A1 (es) |
CY (1) | CY1126107T1 (es) |
DK (1) | DK3250182T3 (es) |
EA (1) | EA201791701A1 (es) |
ES (1) | ES2948805T3 (es) |
FI (1) | FI3250182T3 (es) |
HK (1) | HK1243644A1 (es) |
HR (1) | HRP20230616T1 (es) |
HU (1) | HUE062481T2 (es) |
IL (2) | IL310920A (es) |
LT (1) | LT3250182T (es) |
MA (1) | MA41411B1 (es) |
MD (1) | MD3250182T2 (es) |
MX (1) | MX2017009681A (es) |
PE (1) | PE20171319A1 (es) |
PH (1) | PH12017501331A1 (es) |
PL (1) | PL3250182T3 (es) |
PT (1) | PT3250182T (es) |
RS (1) | RS64308B1 (es) |
SG (1) | SG11201705944TA (es) |
SI (1) | SI3250182T1 (es) |
UA (1) | UA126891C2 (es) |
WO (1) | WO2016120258A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
SI3651736T1 (sl) * | 2017-07-14 | 2021-11-30 | Janssen Pharmaceutica Nv | Formulacije z dolgim delovanjem |
EP3773731A1 (en) * | 2018-04-05 | 2021-02-17 | Cipla Limited | Pharmaceutical formulations |
US11291654B2 (en) * | 2018-09-13 | 2022-04-05 | Syneurx International (Taiwan) Corp. | Formulations of cycloserine compounds and applications thereof |
WO2020123336A1 (en) * | 2018-12-13 | 2020-06-18 | Qrumpharma Inc. | Compositions of bedaquiline, combinations comprising them, processes for their preparation, uses and methods of treatment comprising them |
JP2022516671A (ja) * | 2019-01-09 | 2022-03-01 | ヤンセン ファーマシューティカ エヌ.ベー. | 非結核性抗酸菌症の処置における組合せ |
WO2021257461A1 (en) * | 2020-06-15 | 2021-12-23 | Mylan Laboratories Limited | Combination antibacterial composition and method for antibacterial therapy |
WO2021257466A1 (en) * | 2020-06-15 | 2021-12-23 | The Global Alliance For Tb Drug Development, Inc. | Combination antibacterial composition and method for antibacterial therapy |
CN111888477B (zh) * | 2020-09-15 | 2023-03-07 | 北京福元医药股份有限公司 | 一种贝达喹啉药物制剂 |
KR102478006B1 (ko) | 2020-12-03 | 2022-12-15 | 정승찬 | 자동차 긴급 제동장치 |
US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
GB202211231D0 (en) | 2022-08-02 | 2022-09-14 | Glaxosmithkline Ip No 2 Ltd | Novel formulation |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ538391A (en) | 2002-07-25 | 2005-10-28 | Janssen Pharmaceutica Nv | Quinoline derivatives and their use as mycobacterial inhibitors |
KR101371653B1 (ko) | 2004-05-28 | 2014-03-07 | 얀센 파마슈티카 엔.브이. | 약물 내성 마이코박테리아 질환 치료를 위한 치환된 퀴놀린유도체의 용도 |
EE05394B1 (et) | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
KR101712835B1 (ko) * | 2005-05-25 | 2017-03-07 | 얀센 파마슈티카 엔.브이. | (알파 s, 베타 r)-6-브로모-알파-(2-(디메틸아미노)에틸)-2-메톡시-알파-1-나프탈레닐-베타-페닐-3-퀴놀린에탄올의 제조 방법 |
CA2528849C (en) * | 2005-06-08 | 2014-01-14 | Janssen Pharmaceutica N.V. | Quinoline derivatives as antibacterial agents |
AU2007283196A1 (en) * | 2006-08-10 | 2008-02-14 | Cipla Limited | Antiretroviral solid oral composition |
UA97813C2 (uk) | 2006-12-05 | 2012-03-26 | Янссен Фармацевтика Н.В. | Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу |
JO3271B1 (ar) * | 2006-12-06 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات الكوينولين المضادة للجراثيم |
EP2271320A4 (en) * | 2008-04-02 | 2011-05-18 | Reddys Lab Ltd Dr | PHARMACEUTICAL RALOXIFY FORMULATIONS |
AU2009288820A1 (en) | 2008-09-03 | 2010-03-11 | Pfizer Inc. | Combination therapy for tuberculosis |
US20120207838A1 (en) * | 2011-02-10 | 2012-08-16 | Perricone Nicholas V | Treatment of Psoriasis Using Oral Dosage Forms of Nitrone Spin Traps |
WO2013153162A1 (en) * | 2012-04-11 | 2013-10-17 | Sandoz Ag | Polymorph of rilpivirine hydrochloride |
US20140075692A1 (en) * | 2012-09-18 | 2014-03-20 | Unger Marketing International, Llc. | Multiuse cleaning tool handle |
MX2015006217A (es) * | 2012-11-19 | 2015-11-16 | Azanta As | Tableta dispersable. |
-
2016
- 2016-01-26 PL PL16701516.3T patent/PL3250182T3/pl unknown
- 2016-01-26 CA CA2973301A patent/CA2973301A1/en active Pending
- 2016-01-26 HR HRP20230616TT patent/HRP20230616T1/hr unknown
- 2016-01-26 EP EP16701516.3A patent/EP3250182B1/en active Active
- 2016-01-26 ES ES16701516T patent/ES2948805T3/es active Active
- 2016-01-26 RS RS20230495A patent/RS64308B1/sr unknown
- 2016-01-26 EA EA201791701A patent/EA201791701A1/ru unknown
- 2016-01-26 IL IL310920A patent/IL310920A/en unknown
- 2016-01-26 CN CN201680007314.1A patent/CN107205945A/zh active Pending
- 2016-01-26 CN CN202111218462.7A patent/CN114129526A/zh active Pending
- 2016-01-26 MD MDE20170303T patent/MD3250182T2/ro unknown
- 2016-01-26 SI SI201631721T patent/SI3250182T1/sl unknown
- 2016-01-26 FI FIEP16701516.3T patent/FI3250182T3/fi active
- 2016-01-26 PE PE2017001255A patent/PE20171319A1/es unknown
- 2016-01-26 WO PCT/EP2016/051545 patent/WO2016120258A1/en active Application Filing
- 2016-01-26 PT PT167015163T patent/PT3250182T/pt unknown
- 2016-01-26 IL IL253626A patent/IL253626B1/en unknown
- 2016-01-26 LT LTEPPCT/EP2016/051545T patent/LT3250182T/lt unknown
- 2016-01-26 UA UAA201708632A patent/UA126891C2/uk unknown
- 2016-01-26 DK DK16701516.3T patent/DK3250182T3/da active
- 2016-01-26 SG SG11201705944TA patent/SG11201705944TA/en unknown
- 2016-01-26 HU HUE16701516A patent/HUE062481T2/hu unknown
- 2016-01-26 AU AU2016212116A patent/AU2016212116B2/en active Active
- 2016-01-26 MX MX2017009681A patent/MX2017009681A/es unknown
- 2016-01-26 JP JP2017557493A patent/JP7291458B2/ja active Active
- 2016-01-26 US US15/545,524 patent/US20180000810A1/en not_active Abandoned
- 2016-01-26 KR KR1020177023308A patent/KR102631986B1/ko active IP Right Grant
- 2016-01-26 MA MA41411A patent/MA41411B1/fr unknown
-
2017
- 2017-07-21 PH PH12017501331A patent/PH12017501331A1/en unknown
-
2018
- 2018-03-08 HK HK18103261.6A patent/HK1243644A1/zh unknown
-
2021
- 2021-02-12 JP JP2021020595A patent/JP2021098706A/ja active Pending
- 2021-06-21 AU AU2021204135A patent/AU2021204135B2/en active Active
-
2022
- 2022-02-03 US US17/592,097 patent/US20220331307A1/en not_active Abandoned
- 2022-08-22 JP JP2022131578A patent/JP2022176982A/ja active Pending
-
2023
- 2023-07-07 CY CY20231100319T patent/CY1126107T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20171319A1 (es) | Composiciones dispersables | |
PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
CL2016002414A1 (es) | Compuestos derivados de nucleosidos, inhibidores de la transcriptasa inversas composición farmacéutica que los comprende y su uso en el tratamiento de una infección por vih. pct | |
NI201700011A (es) | 2-(morfolin-4-il)-1,7-naftiridinas. | |
NZ733174A (en) | Quinazoline derivatives used to treat hiv | |
NZ728072A (en) | Modulators of toll-like receptors for the treatment of hiv | |
CL2016000698A1 (es) | Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih | |
CL2015001864A1 (es) | Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih. | |
NZ735575A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
NZ732391A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
WO2017037594A3 (zh) | 用于减少局部脂肪的医药组成物及其用途 | |
MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
MX2016004492A (es) | Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih). | |
IN2013MU03583A (es) | ||
PH12018501237A1 (en) | Isoindole compounds | |
PH12017500569A1 (en) | Compositions and methods for the treatment and prophylaxis of surgical site infections | |
NZ733670A (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
IN2014MU01042A (es) | ||
CR20180091A (es) | 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del vih | |
MX2017003928A (es) | Composiciones farmaceuticas de accion prolongada. | |
CL2016002879A1 (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
WO2016086153A3 (en) | Use of hsp90 inhibitors for the treatment of hiv infections and aids | |
WO2015066302A3 (en) | Compositions, methods of use, and methods of treatment | |
PH12014502834B1 (en) | Pharmaceutical form for extended release of active substances | |
EA201692518A2 (ru) | Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила |